Quote | Dermata Therapeutics Inc. Warrant (NASDAQ:DRMAW)
Last: | $0.0095 |
---|---|
Change Percent: | 3.16% |
Open: | $0.0092 |
Close: | $0.0095 |
High: | $0.0095 |
Low: | $0.0082 |
Volume: | 3,026 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Dermata Therapeutics Inc. Warrant (NASDAQ:DRMAW)
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...
Message Board Posts | Dermata Therapeutics Inc. Warrant (NASDAQ:DRMAW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics, Inc. (NASDAQ: DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuanc...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...